Neoadjuvant HER2+

>

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

Latest News

MRI-guided treatment for duration of neoadjuvant chemotherapy in hormone receptor-negative HER2-positive breast cancer
MRI-Guided Neoadjuvant Chemotherapy Could be Used in HR-/HER2+ Breast Cancer

April 28th 2024

MRI-guided treatment could be used to optimize the duration of neoadjuvant chemotherapy in hormone receptor-negative/HER2-positive breast cancer.

Breast Cancer | adobe.stock.com
Durvalumab Plus Trastuzumab/Pertuzumab Elicits Responses in HER2-Enriched Breast Cancer

April 16th 2024

Aiham Qdaisat, MD, of MD Anderson Cancer Center
Breast-Conserving Therapy Bests Mastectomy After Preoperative Systemic Therapy in HER2+ Breast Cancer

April 9th 2024

Shruti Tiwari, MD, medical oncologist, Virginia Cancer Specialists
Tiwari Highlights Updates in HER2+ and HER2-Low Breast Cancer

April 4th 2024

Debu Tripathy, MD, of The University of Texas MD Anderson Cancer Center
Tripathy Outlines Where the HER2+ Early-Stage Breast Cancer Landscape Stands

April 3rd 2024

More News

Beyond Genetics: Emerging Breakthroughs in Breast Cancer Battle

November 17th 2008

Key findings from the 2008 ASCO Breast Cancer conference; updates on goserelin, capecitabine, docetaxel & lapatinib.

<1
...
434445464748>